Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Shen, Shuhong; Chen, Xiaojuan; Cai, Jiaoyang; Yu, Jie; Gao, Ju; Hu, Shaoyan; Zhai, Xiaowen; Liang, Changda; Ju, Xiuli; Jiang, Hua; Jin, Runming; Wu, Xuedong; Wang, Ningling; Tian, Xin; Pan, Kaili; Jiang, Hui; Sun, Lirong; Fang, Yongjun; Kong Li, Chi; Hu, Qun; Yang, Minghua; Zhu, Yiping; Zhang, Hui; Li, Chunfu; Pei, Deqing; Jeha, Sima; J. Yang, Jun; Cheng, Cheng; Tang, Jingyan; Zhu, Xiaofan; Pui, Ching‐Hon

doi:10.1001/jamaoncol.2019.5868

Public

Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Published in JAMA Oncology • Jan 16, 2020

Authors:

Shuhong Shen

Xiaojuan Chen

Jiaoyang Cai

Abstract

Importance: A randomized clinical trial is needed to determine whether the second-generation Abl-tyrosine kinase inhibitor dasatinib is more effective than the first-generation inhibitor imatinib mesylate for childhood Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Objective: T...

Subject

Medicine

Dasatinib

Imatinib mesylate

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!